Artemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycle

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 1, 2009, Pages 146-150

  D'Angelo, John G ^a,b,c   Bordón, Claudia ^b   Posner, Gary H ^a   Yolken, Robert ^b   Jones Brando, Lorraine ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALFRED UNIVERSITY   (United States)

Author keywords

Antiparasitic drugs; In vitro inhibition; Parasite; Toxoplasmosis; Treatment

Indexed keywords

ARTEMETHER; ARTEMISININ DERIVATIVE; BETA GALACTOSIDASE; TRIMETHOPRIM;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; FIBROBLAST; GROWTH INHIBITION; HOST CELL; HOST PARASITE INTERACTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION; TACHYZOITE; TOXOPLASMA GONDII;

ANIMALS; ANTIPROTOZOAL AGENTS; ARTEMISININS; CELLS, CULTURED; FIBROBLASTS; HUMANS; INHIBITORY CONCENTRATION 50; TOXOPLASMA;

EID: 57649222343     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn451     Document Type: Article

References (13)

1. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004; 363: 1965-76.
2. Vogel N, Kirisits M, Michael E et al. Congenital toxoplasmosis transmitted from an immunologically competent mother infected before conception. Clin Infect Dis 1996; 23: 1055-60.
3. Georgiev VS. Management of toxoplasmosis. Drugs 1994; 48: 179-88.
4. Ou-Yang K, Krug EC, Marr JJ et al. Inhibition of growth of Toxoplasma gondii by qinghaosu and derivatives. Antimicrob Agents Chemother 1990; 34: 1961-5.
5. Jones-Brando L, D'Angelo J, Posner GH et al. In vitro inhibition of Toxoplasma gondii by four new derivatives of artemisinin. Antimicrob Agents Chemother 2006; 50: 4206-8.
6. O'Neill PM, Searle NL, Kan K-W et al. Novel, potent, semi-synthetic antimalarial carba analogues of the first-generation 1,2,4-trioxane artemether. J Med Chem 1999; 42: 5487-93.
7. Jones-Brando L, Torrey EF, Yolken RH. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res 2003; 62: 237-44.
8. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27: 493-9.
9. Silverman JA, Hayes ML, Luft BJ et al. Characterization of anti- Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiology. Antimicrob Agents Chemother 1997; 41: 1859-66.
10. Huynh M-H, Carruthers V. Toxoplasma MIC2 is a major determinant of invasion and virulence. PLoS Pathog 2006; 2: 753-62.
11. Huynh M-H, Rabenau KE, Harper JM et al. Rapid invasion of host cells by Toxoplasma requires secretion of the MIC2-M2AP adhesive protein complex. EMBO J 2003; 22: 2082-90.
12. Pfefferkorn ER, Nothnagel RF, Borotz SE. Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant. Antimicrob Agents Chemother 1992; 36: 1091-6.
13. Nagamune K, Beatty WL, Sibley LD. Artemisinin induces calcium-dependent protein secretion in the protozoan parasite Toxoplasma gondii. Eukaryot Cell 2007; 6: 2147-56.